LONDON (Alliance News) - GlaxoSmithKline PLC's joint venture ViiV Healthcare Ltd said Monday its phase IIIb study of Triumeq showed superior efficacy in the treatment of treatment-naive women living with HIV.
The 48 week study compared Triumeq with a treatment of atazanavir boosted with ritonavir plus tenofovir disoproxil fumarate/emtricitabine, and found that Triumeq produced "statistically superior viral suppression" rates at week 48.
Treatment naive refers to patients who have never undergone a treatment for a particular illness.
"Women account for over half of the almost 35 million adults living with HIV worldwide, yet unfortunately they are consistently under-represented in HIV clinical trials", said John Pottage Jr, ViiV Healthcare's chief scientific and medical officer.
"For this reason, we are committed to ensuring that the specific treatment needs of women are investigated. This trial not only provides physicians with important additional information about Triumeq, it also builds on the strong body of evidence supporting the efficacy of dolutegravir-based regimens in a broad range of patient populations," Pottage added.
ViiV is a joint venture among Glaxo, Pfizer Inc and Shionogi Ltd.
Shares in Glaxo were down 0.2% at 1,646.00 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)